.Pharmacolibrary.Drugs.ATC.J.J05AR28 .Pharmacolibrary.Drugs.ATC.J.J05AR28| name: | StavudineAndLamivudine | |
| ATC code: | J05AR28 | route: | oral |
| compartments: | 1 | |
| dosage: | 40 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 25 | L/hr |
| other parameters in model implementation | ||
Stavudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) used in combination for the treatment of HIV-1 infection. The fixed-dose combination is classified under ATC code J05AR28 and is intended to suppress viral replication in HIV-positive individuals. Both drugs are approved and used within antiretroviral therapy regimens but have largely been replaced by newer, less toxic alternatives in high-income settings. The fixed-dose combination may still be used in resource-constrained settings.
No published population pharmacokinetic studies found for the fixed-dose combination of stavudine and lamivudine. Below are rough estimated parameters based on published PK data for the individual drugs in healthy adults after oral administration.